Clinical Trial Update: A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer [Phase 3]

View source ↗

Summary

Phase III study evaluating HLX10 plus chemotherapy for advanced cervical cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• HLX10

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Cervical Cancer | Phase 3 | Status: WITHDRAWN